Core Insights - Lantheus Holdings, Inc. is presenting real-world evidence of PYLARIFY's effectiveness in detecting recurrent prostate cancer at the 2025 ASCO Genitourinary Cancers Symposium [1][2] - PYLARIFY is the leading PSMA-targeted PET imaging agent in the U.S., with over 400,000 scans conducted across 48 states [3] Presentation Details - The presentation will occur on February 13, 2025, during two time slots: 11:25 am – 12:45 pm PT and 5:45 PM-6:45 PM PT [2] - The session will include two posters: one on early detection of recurrent prostate cancer and another on the role of conventional imaging and PYLARIFY in prostate cancer patients [2] Product Information - PYLARIFY (piflufolastat F 18) is a PSMA-targeted PET imaging agent that allows visualization of metastatic prostate cancer [3] - The recommended dose for PYLARIFY is 333 MBq (9 mCi), with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi) [3] Company Overview - Lantheus is a leading company in the radiopharmaceutical sector, focused on improving patient outcomes through innovative diagnostic solutions [11]

Core Insights - Lantheus Holdings, Inc. has appointed Dr. Phuong Khanh (P.K.) Morrow to its Board of Directors, effective February 1, 2025, enhancing its leadership in radiopharmaceuticals [1][2] - Dr. Morrow brings extensive experience in oncology and drug development, which aligns with Lantheus' strategic initiatives and innovation efforts [2][3] - Following this appointment, the Board will consist of eleven directors, with nine being independent, reflecting a strong governance structure [1] Company Overview - Lantheus is a leading company focused on radiopharmaceuticals, dedicated to enabling clinicians to Find, Fight, and Follow disease for improved patient outcomes [3] - The company has been providing radiopharmaceutical solutions for over 65 years and is headquartered in Massachusetts, with additional offices in Canada and Sweden [3]

Core Insights - Lantheus Holdings, Inc. announced the appointment of Dr. Phuong Khanh (P.K.) Morrow to its Board of Directors, effective February 1, 2025, enhancing its leadership in radiopharmaceuticals [1][2] - Dr. Morrow brings extensive experience in oncology and drug development, which aligns with Lantheus' strategic initiatives and innovation efforts [2][3] - Following this appointment, the Board will consist of eleven directors, with nine being independent, reflecting a strong governance structure [1] Company Overview - Lantheus is a leading company focused on radiopharmaceuticals, dedicated to enabling clinicians to Find, Fight, and Follow disease for better patient outcomes [3] - The company has been providing radiopharmaceutical solutions for over 65 years and is headquartered in Massachusetts, with additional offices in Canada and Sweden [3]

Radiopharmaceutical specialist Lantheus Holdings (LNTH -7.30%) had some news to report Tuesday morning, but the market didn't greet it warmly. Following its announcement of a fresh acquisition, investors traded out of the niche healthcare stock, leaving it with a more than 7% loss on the day. That was in contrast with the S&P 500 index, which increased by 0.9%.New day, new dealWell before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage peer Ev ...

Core Insights - Lantheus Holdings, Inc. has announced a definitive agreement to acquire Evergreen Theragnostics, Inc. for an upfront payment of $250 million and potential milestone payments of up to $752.5 million, enhancing its position in the radiopharmaceutical sector [2][7] - The acquisition is expected to solidify Lantheus' capabilities as a fully integrated radiopharmaceutical company, adding scalable manufacturing infrastructure and expanding its oncology diagnostic pipeline with the addition of OCTEVY, a diagnostic agent for neuroendocrine tumors [3][5] - Lantheus reaffirms its financial guidance for the full year and fourth quarter of 2024, projecting revenues between $1.51 billion and $1.52 billion and adjusted fully diluted EPS between $6.65 and $6.70 [8] Acquisition Details - The acquisition of Evergreen is aimed at enhancing Lantheus' manufacturing capabilities, particularly in radioligand therapy (RLT) and Contract Development and Manufacturing (CDMO) services, which will support long-term growth and mitigate third-party risks [5][6] - OCTEVY, a registrational-stage diagnostic imaging agent, is expected to complement Lantheus' therapeutic candidate PNT2003, potentially being used as a theranostic pair for treating neuroendocrine tumors [5][6] - The transaction has been approved by the Boards of Directors of both companies and is expected to close in the second half of 2025, pending regulatory clearances [7] Strategic Rationale - The acquisition is positioned as a strategic move to enhance Lantheus' operational capabilities across the radiopharmaceutical value chain, allowing for better patient outcomes through improved manufacturing and development processes [4][5] - Evergreen's expertise in drug discovery and early-stage clinical development is expected to enrich Lantheus' oncology pipeline and accelerate the delivery of innovative therapies to patients [4][5] - The integration of Evergreen's team and capabilities is anticipated to foster a culture focused on developing new solutions for cancer patients, aligning with Lantheus' mission [4][6]

Enhances Lantheus' growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease Advances Lantheus' radiopharmaceutical leadership with addition of Alzheimer's radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&D capabilities Transaction expected to be accretive to adjusted EPS within the first 12 months Company to host conference call on January 13, 2025, at 8:30 AM EST BEDFORD, Mass., Ja ...

Acquisition Overview - Lantheus Holdings Inc announced a definitive agreement to acquire Life Molecular Imaging Ltd in an all-cash transaction consisting of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments [1] - The transaction is expected to close in the second half of 2025, subject to customary closing conditions including regulatory approvals [6] - The acquisition is expected to be accretive to Lantheus' Adjusted Earnings Per Share within 12 months of close [2] Strategic Rationale - The acquisition establishes a commercial Alzheimer's disease (AD) franchise with the addition of Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease [1][2] - Life Molecular brings robust R&D capabilities, a strong commercial infrastructure, and an established international presence, which Lantheus plans to utilize to accelerate the development and commercialization of the combined company's pipeline [2] - The acquisition complements Lantheus' pipeline with the addition of highly complementary radiodiagnostic clinical-stage assets targeting diseases with significant unmet needs [4] Financial Impact - The transaction is expected to immediately enhance Lantheus' near and long-term growth profile [2] - Lantheus expects to maximize access to Neuraceq for the approximately 55 million people around the world who are living with AD or mild cognitive impairment [4] - The acquisition builds on Lantheus' June 2024 acquisition of the global rights to LMI's clinical-stage radiotherapeutic and radiodiagnostic pair, 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2, which target gastrin-releasing peptide receptor (GRPR) for prostate, breast and other cancers [5] Product Details - Neuraceq is indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline [13] - The overall safety profile of Neuraceq is based on data from 1,090 administrations of Neuraceq to 872 subjects, with no serious adverse reactions reported [10] - Neuraceq is commercially approved in the United States, Canada, Europe, the UK, Switzerland, China, Japan, South Korea, and Taiwan [20] Company Background - Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes [15] - Life Molecular Imaging is a global radiopharmaceutical company dedicated to developing and offering novel cutting-edge radiopharmaceuticals that improve early detection and characterization of chronic and life-threatening diseases [19] - Life Healthcare, the parent company of Life Molecular, is a global people-centered, diversified healthcare organization with over 40 years' experience in the South African private healthcare sector [11]

Short-term market predictions are fun, but rarely worth investing in. Here are two stocks we think will be winners no matter what happens with the market in 2025.In this video, Motley Fool contributors Jason Hall and Tyler Crowe make two predictions about the market in 2025, and also share two stock picks they think will do well no matter what happens with the market this year: Lantheus (LNTH -1.26%) and Synopsys (SNPS -0.99%).*Stock prices used were from the afternoon of Dec. 18, 2024. The video was publis ...

This is a complementary article on my previous piece about Henry Schein (NASDAQ: HSIC ) which can be found here . That research stemmed from a screen of midcap stocks that led to the following six companies. In my effort toI am a conservative yet opportunistic value investor who has been investing since 2005. I am fact-driven, preferring to let financial data inform me of a company's health, followed by qualitative analysis to fill in the gaps to paint a holistic picture of a company's growth prospects.My w ...

The stock of radiopharmaceutical specialist Lantheus Holdings (LNTH 8.84%) was a standout in the healthcare sector on Hump Day. The company saw its share price improve by almost 9% at market close, thanks to news of a shareholder-pleasing move. That gain far outpaced the S&P 500 index, which ended up closing flat on the day.A $250 million moveWell before market open, Lantheus announced the launch of a $250 million share repurchase program. The initiative will be in force for one year. As is typical for stoc ...